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Abstract. Three-dimensional (3D) lung multicellular spher-
oids (MCS) in liquid-covered culture (LCC) and air-interface 
culture (AIC) conditions have both been developed for the 
evaluation of aerosol anticancer therapeutics in solution and 
aerosols, respectively. The MCS were formed by seeding lung 
cancer cells on top of collagen where they formed spheroids 
due to the prevalence of cell-to-cell interactions. LCC MCS 
were exposed to paclitaxel (PTX) in media whereas AIC 
MCS were exposed to dry powder PEGylated phospholipid 
aerosol microparticles containing paclitaxel. The difference 
in viability for 2D versus 3D culture for both LCC and AIC 
was evaluated along with the effects of the particles on lung 
epithelium via transepithelial electrical resistance (TEER) 
measurements. For LCC and AIC conditions, the 3D spheroids 
were more resistant to treatment with higher IC50 values for 
A549 and H358 cell lines. TEER results initially indicated 
a decrease in resistance upon drug or particle exposure, 
however, these values increased over the course of several 
days indicating the ability of the cells to recover. Overall, 
these studies offer a comprehensive in vitro evaluation of 
aerosol particles used in the treatment of lung cancer while 
introducing a new method for culturing lung cancer MCS in 
both LCC and AIC conditions. 
Introduction
Patients in the United States die from lung cancer more than 
any other individual cancer diagnosis (1). While surgical resec-
tion is the standard of care for early stage lung cancer, only 
25% of patients have resectable disease at the time of diag-
nosis (2). As a result, current practice guidelines recommend 
these patients be treated with a combination of chemotherapy 
and radiation (3). In vitro cell culture models are a major factor 
in analyzing the effectiveness of cancer therapeutics. In lung 
cancer specifically, there are many characteristics of a tumor 
that need to be altered in an in vitro cell culture model in order 
for it to be as physiologically representative as possible. In 
order to do this, many aspects of the cell culture methods have 
to be improved. Specifically, a model that is three-dimensional 
(3D), possesses a surrounding environment that is similar to 
an in vivo tumor, yields proliferating cells, and is set up so 
that cells can be exposed to air (as cancer cells are in the lung) 
needs to be established.
To start, the use of 3D multicellular spheroids (MCS) 
allows for a more tumor-like environment to evaluate chemo-
therapeutic drugs. MCS are small, tightly bound cellular 
aggregates that tend to form when cells are maintained under 
non-adherent conditions. These aggregates can range in size 
from 20 µm up to 1 mm in diameter depending on the cell 
type and growth conditions (4). Testing anticancer drugs in 3D 
culture models will better simulate the tumor microenviron-
ment and signaling pathways that are functional in tissues and 
organs and can potentially provide a better correlation between 
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in vitro screening and in vivo animal models (5). Tumor 
spheroids are also considered an improved in vitro model to 
mimic biological properties of micrometastases and vessel 
distal regions of tumors because they retain the architecture 
and many morphological and physiological characteristics of 
their tumor counterparts (6).
MCS can mimic avascular in vivo tumors in that they have 
diffusion limitations for many molecules, including oxygen, 
and this inefficient mass transport leads to metabolic waste 
accumulation inside the MCS so that they display a layer-like 
structure comprised of a necrotic core surrounded by a viable 
rim of cells (7,8). It is the center of a tumor that exhibits a 
hostile microenvironment. This environment harbors the 
most aggressive tumor cells, which will regenerate if they 
are not eliminated. MCS have been effectively used to study 
many types of therapeutics including nanoparticles, chemo-
therapeutics, and radiation where the MCS show significant 
differences in response in comparison to two-dimensional 
(2D) cell monolayers (9,10). Most chemotherapeutic drugs 
affect actively proliferative tumor cells by either crosslinking 
DNA or interfering with the formation of the mitotic spindle. 
It is expected that these types of drugs would have a lesser 
effect on 3D MCS, which have a large fraction of quiescent 
cells. Also, the reduced diffusion of drugs through multiple 
cell layers and increased expression of drug transporters can 
result in drug resistance in MCS (11).
There are many methods for creating 3D MCS, the 
most common of these include liquid overlay, embedding 
in extracellular matrix (ECM) components, hanging drop, 
micromolding, spinner flask, rotary culture, and centrifuga-
tion methods (7,12). Several of these methods have been 
utilized in the development of 3D spheroid models of lung 
cancer for the evaluation of solution-based anticancer thera-
peutics. For example, both A549 lung adenocarcinoma cells 
and primary lung cancer cells have been grown via the liquid 
overlay method on agarose (13,14) or poly(2-hydroxyethyl 
methacrylate) (pHEMA) (6). Vertrees et al created spheroids 
of a transformed cell line (bZR-T33) over several weeks in 
a rotating wall vessel (15). A high throughput method of 
spheroid creation was developed where H1650 lung cancer 
cells were formed in mini-ports on a microchip (16). A549 
spheroids were embedded in Matrigel™ which contains ECM 
components and both A549 and H358 cells were embedded 
in collagen for the formation of spheroids (5,17,18). Despite 
these initial studies, they all pose disadvantages in the study 
of aerosol therapeutics including drug diffusion limitations 
through ECM-based matrices for the embedded method, chal-
lenges in implementation for the microchip method, the need 
for specialized equipment for rotating wall vessel method, and 
lack of air-interface conditions for the liquid overlay method.
The purpose of this current study was develop an in vitro 
lung tumor spheroid model that could mimic in vivo tumor 
shape, behavior, and environment more closely and effectively 
and to observe the effects of both solution-based and aerosol-
based therapeutics on this model. In liquid overlay culture, 
culture plates are usually coated with a non-adhesive, partially 
hydrophilic material to create a surface on which the cells, 
once seeded, are more inclined to attach to each other than to 
the culture surface, thereby initiating the formation of spher-
oids on the surface of the collagen. The spheroids are grown in 
solution using a liquid-covered culture (LCC) method which 
allows for the evaluation of drug in solution. Subsequently, 
this system can be modified where the spheroids are formed 
on collagen in Transwells® where the media is then removed 
to allow the spheroids to be grown in air-interface culture 
(AIC) conditions. This will allow for the evaluation of 
aerosol-based therapeutics.
One of the current limitations in the evaluation of aerosol-
based therapeutics for lung cancer is the lack of cell culture 
models for the evaluation of their efficacy. The described work 
allows for the evaluation of effectiveness of such therapeutics 
on 2D cells and 3D spheroids grown in AIC conditions as 
well as the evaluation of the safety of these systems using 
transepithelial resistance (TEER) analysis. When grown using 
AIC, primary cell layers resemble the native epithelium to a 
greater extent than cells grown using LCC (19). Furthermore, 
the growth of spheroids in AIC conditions is more physiologi-
cally representative than LCC and allows the direct testing of 
aerosol therapeutics on the cells rather than having to dissolve/
disperse them in solution. TEER is a measurement of the 
electrical resistance across a cell monolayer and this measure-
ment can be used to analyze the permeability of the cells in 
a monolayer. TEER reduction has been used as an indication 
of adverse effects of model toxicants and inhaled delivery 
vehicles and corresponds well with standard toxicological 
tests (20,21). Ensuring that there is no significant change in 
the permeability of lung cancer cells is important in showing 
the safety of the aerosol therapeutic. Calu-3 lung cells have 
already been established for use in TEER studies for both 
LCC and AIC conditions (19,22,23).
Paclitaxel (PTX) was selected as the model therapeutic 
as it is widely used in the treatment of non-small cell lung 
cancer via intravenous delivery (24,25) and is being inves-
tigated in aerosolized formulations for the treatment of 
lung cancer (26-28). Our group has developed dry powder 
PEGylated phospholipid microparticles containing PTX that 
show optimized aerodynamic diameters, release, and aerosol 
dispersion properties (29,30). These were selected to act as 
the model for an aerosol treatment for lung cancer for the 
validation of the AIC 3D MCS model. Overall, this study 
outlined the pertinent physicochemical characteristics of the 
dry powder aerosol microparticles, which were used and the 
in vitro characterization of both the dry powders and PTX in 
solution. This particular characterization included evaluating 
the activity of the PTX encapsulated in the particles, uptake of 
the particles into A549 cells, development of the lung MCS in 
LCC and AIC conditions, efficacy of the solution-based and 
aerosol particle treatments, and safety of the aerosol particles 
using TEER. These studies may potentially act as a model for 
the more comprehensive evaluation into the efficacy and safety 
of aerosol particles in vitro prior to more time-consuming and 
expensive in vivo experiments.
Materials and methods
Materials. Fetal bovine serum (FbS), penicillin-streptomycin 
solution and trypsin/EDTA were obtained from American 
Type Culture Collection (ATCC, Manassas, VA). Calcein AM, 
ethidium homodimer-1, Dulbecco's modified Eagle's medium 
(DMEM), sodium pyruvate, Fungizone®, Lysotracker® Red, 
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Hoescht 3342, and L-glutamine were obtained from Invitrogen 
(Grand Island, NY, USA). DMSO and resazurin sodium salt 
were obtained from Sigma-Aldrich (St. Louis, MO, USA) 
and collagen I (rat tail) was from bD biosciences (San Jose, 
CA, USA). Synthetic dipalmitoylphosphatidylcholine (DPPC, 
molecular weight (MW): 734.039 g/mol; >99% purity) and 
dipalmitoylphosphatidylethanolamine-methoxy(polyethylene 
glycol) (DPPE-PEG3k, MW 3716.304 g/mol which corre-
sponds to 3000 molecular weight poly(ethylene glycol) length 
per compound; >99% purity) were obtained from Avanti Polar 
Lipids (Alabaster, AL, USA). Paclitaxel was obtained from LC 
Laboratories (Woburn, MA, USA; 99.5% purity). All materials 
were used as received.
Cell lines and culturing conditions. H358 (bronchioalveolar 
carcinoma) and A549 (lung adenocarcinoma) cells were 
obtained from ATCC and were cultured in medium comprised 
of DMEM, 10% FbS, 4 mM L-glutamine, 1 mM sodium pyru-
vate, 0.25 µg/ml Fungizone, 100 IU penicillin, and 100 µg/ml 
streptomycin. The cells were grown at 37˚C and 5% CO2 in a 
humidified atmosphere.
Dry powder particle synthesis and PTX loading. Dry aerosol 
powders were synthesized via spray drying as described previ-
ously by our group (29,30). PEGylated phospholipid particles 
were made by mixing DPPC and DPPE-PEG3k (95:5 molar 
ratio) with 1, 5, 25, and 50 mol% paclitaxel relative to the total 
phospholipid amount in methanol (hereby abbreviated as 1% 
PTX MPs, 5% PTX MPs, 25% PTX MPs, and 50% PTX MPs, 
respectively, where MPs refers to microparticles). The solutions 
were then spray dried to produce particles approximately 1 µm 
in diameter (30). UV-Vis was used to determine the amount 
of paclitaxel loaded into the formulated particle systems. The 
particles were dissolved in known quantities of methanol prior 
to analysis. The absorbance intensity was measured at 227 nm 
using a Synergy Mx bioTek microplate reader. The paclitaxel 
encapsulation efficiency (EE) and loading was calculated as 
follows:
                         Actual mass of PTX               EE = ----------------------------------------- x 100%       (1)
                         Initial mass of PTX
                                  Actual mass of PTX        Drug loading = ---------------------------------------           (2)
                                  Mass of particles
Particle internalization/Uptake study. A549 cells were 
exposed to 25% PTX MPs loaded with 1 mol% nitrobenzoxa-
diazole phosphatidylcholine (NBD-PC) to allow for fluorescent 
imaging of the particles. Cells/well (60,000) were seeded into 
an 8-well chamber slide and were left to attach for 24 h. They 
were then exposed to 1 mg/ml of particles in media for 6 and 
24 h. After exposure, the cells were washed with a 200 mM 
glycine solution to remove any non-internalized particles and 
were then stained with 7.5 nM Lysotracker Red and 10 µM 
Hoescht 33342 prior to live imaging. Imaging was completed 
using a Nikon Eclipse 80i microscope.
A549 viability/Particle activity study. The activity of the 
paclitaxel present in the particles was evaluated by exposing 
A549 cells to various concentrations of PTX-loaded micro-
particles and free (raw) paclitaxel. A549 cells were seeded at 
3,000 cells/well in 96-well plates for 48 h followed by expo-
sure to PTX-loaded particles or PTX diluted in DMSO from 
0.0001 to 1 µM in media. The PTX was initially dissolved in 
DMSO at its highest solubility and then diluted with media 
for further PTX concentrations. The amount of DMSO was 
kept constant at 0.1% v/v for all PTX concentrations (also the 
control), including for PTX-loaded microparticle samples. A 
control of particles without PTX was also evaluated using the 
same amount of particles as the particle system with the lowest 
concentration of PTX. At 72 h after exposure, the cells were 
exposed to 2 mM of resazurin for 3 h. The fluorescence inten-
sity of the resulting resorufin was measured using a Synergy 
Mx bioTek microplate reader at 579/584 nm (excitation/emis-
sion) wavelengths. The relative viability was then evaluated 
as the fluorescence intensity of the sample divided by the 
fluorescence intensity of control cells (no treatment).
Two-dimensional cell culture evaluation of paclitaxel and 
paclitaxel-loaded dry powder particles. Cells were grown in 
both air-interface culture (AIC) and liquid-covered culture 
(LCC) conditions to determine the half-maximal inhibitory 
concentration (IC50) for 2D culture conditions. For the LCC 
condition, H358 and A549 cells were seeded in 96-well plates 
at 7,500 and 3,000 cells/well, respectively. After 48 h, the cells 
were exposed to PTX (0.0001 to 1 µM) where all PTX solu-
tions contained 0.1% (v/v) DMSO in medium to aid in PTX 
solubility. For AIC conditions, H358 and A549 cells were 
seeded in Transwells (0.4 µm polyester membrane, 12 mm, 
12-well plate) at 22,000 and 14,000 cells/well, respectively, 
with 0.5 ml media on the apical side and 1.5 ml of media on 
the basolateral side of the Transwell. At 24 h after seeding, 
media was removed from the apical side and the basolateral 
side was reduced to 0.5 ml to induce AIC conditions. After a 
further 24 h, the cells were exposed to 1 mg of each particle 
type (blank, 1, 5, and 25% PTX MPs) using a 1 ml syringe 
and 21G needle to aerosolize the particles onto the cells. At 
72 h after exposure to PTX, the viability of the cells was 
determined via a resazurin (viability) assay as described 
above (0.5 ml of media was added to the AIC cells prior to 
the analysis). IC50 values were determined using SigmaPlot 
12.0 software.
Three-dimensional multicellular spheroid (MCS) forma-
tion. MCS were formed on type I rat tail collagen which was 
used because of its non-adhesive nature to more prominently 
induce cell-to-cell interactions. LCC and AIC conditions were 
induced by seeding cells onto collagen in 24-well plates and 
Transwell, respectively, and the visualization of this process 
can be seen in Fig. 1. Collagen solution was mixed according 
to the manufacturer's instructions. A 2.1 mg/ml collagen solu-
tion was pipetted into the plates and allowed to solidify at 37˚C 
in an incubator for 30 min. H358 and A549 cells were seeded 
at 10,000 cells/well and 7,500 cells/well, respectively (0.5 ml 
media and cells on the apical and 1.5 ml of media on the baso-
lateral side of the Transwells for AIC). For AIC conditions, the 
media was removed from the apical side after 24 h. The size 
and morphology of the spheroids was determined via bright 
field imaging. During their growth and formation, the MCS 
were imaged daily and their diameter was analyzed using 
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NIS-Elements software. both to PTX exposure as well as at 
the end of PTX exposure, the spheroids were stained using 
calcein AM and ethidium homodimer-1 and imaged to show 
the presence in live and dead cells, respectively.
Three-dimensional MCS evaluation of paclitaxel and pacli-
taxel-loaded dry powder particles. The cells were grown until 
spheroid formation was evident (4 days for H358 and 9 days 
for A549 cells). The evaluation of the effect of PTX on MCS 
was determined by exposing the cells to PTX utilizing the 
LCC condition and AIC condition where the drug was applied 
to the air interface of the cells via phospholipid dry powder 
aerosol containing PTX. For the LCC condition, the MCS 
were exposed to 0.0001 to 1 µM PTX and for AIC condition, 
the MCS were exposed to blank, 1, 5 and 25% PTX MPs as 
described above. After 72 h, viability was determined using the 
resazurin assay. IC50 values were determined using SigmaPlot 
12.0 software.
Transepithelial electrical resistance (TEER) analysis on lung 
cell monolayers. TEER evalution was completed using an 
EVOM2 epithelial voltammeter and 12 mm Endohm culture 
cup from World Precision Instruments (Sarasota, FL, USA). 
Calu-3 cells were seeded at 250,000 cells/well in Transwells. 
To induce AIC conditions, the media was removed from the cell 
monolayer after 24 h and was replaced and removed for TEER 
measurement only. TEER values were measured every other 
day for both AIC and LCC conditions. Upon reaching resis-
tance equilibrium (after 5 days), the monolayer was exposed 
to phospholipid dry powder particles with or without PTX 
(AIC condition) as well as PTX in media (LCC condition). The 
resistance of the monolayer was again measured 2, 4, 24, 48, 
72, 96 and 120 h after PTX or particle exposure. The reported 
resistance values are the actual resistance less the resistance 
due to a blank Transwell.
Results and Discussion
Dry powder PEGylated phospholipid microparticles (MPs) 
were used as a model system to demonstrate the validity of 
a 3D air-interface culture (AIC) multicellular spheroid model 
in the evaluation of aerosol lung therapeutics. The particles 
were loaded with paclitaxel (PTX) at 1, 5, 25, and 50 mol%. 
Our previous work shows these particles to be approximately 
1 µm in diameter (30). PTX encapsulation efficiencies (EE) 
were high for all particle systems (at least 96.6 weight %) and 
the actual EE values are listed along with the actual PTX load-
ings (mg PTX/mg particles) in Table I. This is ideal for aerosol 
drug delivery systems especially as it allows for the maximum 
amount of drug loading in the particle, allowing for minimal 
excess powder delivery while still maintaining optimal treat-
ment properties. 
The effect of the particles on lung cells was initially 
evaluated via both uptake and liquid-covered culture (LCC) 
viability studies. A549 cells were exposed to 1 mg/ml of 50% 
PTX MPs (the highest PTX loading) containing fluorescent 
NbD in media for 6 and 24 h. Fig. 2 includes representa-
tive combined fluorescent micrographs of cells exposed to 
particles and the subsequent controls. At 6 h, there was some 
uptake of particles evident (green) with a significant amount 
of lysosome staining (red) where the nuclei were stained blue. 
The morphology and staining was similar for the control cells 
at 6 h in comparison to the cells exposed to particles. After 
the 24 h particle exposure, there was also particle uptake 
evident, however, there were much fewer cells attached to 
the slides in comparison to the control. This is likely due to 
the significant amount of cell death that would have occurred 
for this exposure time and PTX concentration. Overall, these 
results demonstrate the capability of the particles to inter-
nalize within lung epithelial cells, potentially enhancing the 
delivery of paclitaxel.
The activity of PTX in the particles after spray drying was 
evaluated by dispersing the particles in media and exposing 
A549 cells to various concentrations of PTX for 72 h to 
produce a dose-response curve. The viability for blank parti-
cles (without PTX) was 99±2% which was not significantly 
different from the control (p>0.9). While the resulting IC50 
value of raw PTX (no spray drying) was 0.0346 µM, the IC50 
values for the particles ranged from 0.0028 to 0.0053 µM for 
the particle systems as seen in Table I. This 10-fold decrease 
in IC50 values could be due to the uptake of the particles 
into A549 cells and subsequent PTX release or as a result 
of paclitaxel binding with the serum present in the media, 
decreasing the effective dose of raw paclitaxel in media. In 
Table I. PEGylated phospholipid microparticle systems con-
taining paclitaxel, actual PTX encapsulation efficiency (EE), 
actual loading of PTX and PTX IC50 values corresponding to 
dose-response curve.
 Actual  PTX Loading PTX IC50
 PTX EE (mg PTX/mg (µM)
System (wt %) particles)
Raw PTX NA NA 0.0346
1% PTX MPs 99.1±2.2 0.010±0.001 0.0053
5% PTX MPs 96.6±1.2 0.059±0.007 0.0047
25% PTX MPs 95.9±3.1 0.268±0.009 0.0030
50% PTX MPs 98.2±2.1  0.512±0.008 0.0028Figure 1. Schematic depicting liquid overlay culture (LCC) condition versus 
AIC conditions in the culturing of lung cancer multicellular spheroids (MCS).
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the end, these results demonstrate that paclitaxel retains its 
efficacy and activity against lung cancer cells after spray 
drying and increases the efficacy by its targeted delivery to 
the cells.
A 3D lung cancer multicellular spheroid (MCS) model was 
formed by seeding either A549 or H358 cells onto collagen in 
either liquid-covered culture (LCC) or air-interface culture 
(AIC) conditions. Fig. 3 shows micrographs of the resulting 
3D spheroids grown in AIC conditions with time. For H358 
cells, spheroids formed fairly quickly after seeding (within 
two days) with a distribution of sizes whereas A549 form 
loose spheroid aggregates only after 9 days of cell culture. 
Spheroids grown in LCC conditions were visually the same 
in size and morphology as those in AIC conditions for both 
cell lines (data not shown). The spheroids were fluorescently 
stained to show cell viability and death after 6 or 12 days of 
culturing (H358 and A549 cells, respectively), which is the 
final growth time after treatment with PTX or PTX-loaded 
MPs. H358 cells were almost entirely alive (green) whereas 
A549 cells showed some cell death (red). These results indicate 
that the spheroids were able to maintain their growth profiles 
and stay alive with nutrient transfer through the collagen layer 
throughout their growth and treatment with paclitaxel. While 
efficacy experiments were completed on both cell lines, it may 
Figure 2. Representative fluorescent micrographs of A549 cells used in PEGylated phospholipid microparticle uptake studies where (A and B) are after 6 h of 
exposure, (C and D) are after 24 h of exposure. Cells in (A and C) were exposed to 1 mg/ml of 25% PTX MPs whereas (b and D) are control cells. blue, red, 
and green fluorescent staining represent the cell nuclei, cell cytoskeleton, and microparticles, respectively. Scale bar, 50 µm.
Figure 3. Representative micrographs of an air-interface culture (AIC) condition 3D spheroid formation including bright field images and final day fluorescent 
images (with respect to time) where green cells stained with calcein are alive and red cells stained with ethidium homodimer-1 are dead. Scale bar, 200 µm.
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be that H358 cells provide a better model for fully formed, 
spherical spheroids grown on collagen in the evaluation of 
lung anticancer therapeutics (Fig. 4).
To provide a baseline comparison to the 3D MCS models 
(both AIC and LCC), PTX and PTX-loaded particles were 
also evaluated using 2D-cultured cells in both LCC and 
AIC conditions, respectively. Dose-response curves for both 
cell types and both 2D and 3D culturing conditions can be 
seen in Fig. 5. The actual PTX dose for the AIC studies was 
determined by using the actual amount of PTX loaded in the 
particles (Table I) and the amount of powder dose provided to 
each sample/well of cells (1 mg) resulting in units of mg/dose. 
The resulting IC50 values can be found in Table II. For LCC 
conditions, 3D cells exhibited a delayed lag in response on 
Figure 5. Dose-response curves of lung cancer cell lines exposed to PTX and PTX-loaded aerosol microparticles in the following conditions: (A) A549 cells 
exposed to raw PTX in LCC conditions, (b) H358 cells exposed to raw PTX in LCC conditions, (C) A549 cells exposed to PTX-loaded microparticles in AIC 
conditions, and (D) H358 cells exposed to PTX-loaded microparticles in AIC conditions.
Figure 4. Spheroid diameter/growth curves for (A) H358 and (b) A549 3D spheroids in LCC conditions during spheroid formation and after treatment with 
paclitaxel in media.
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the dose-response curve corresponding to higher IC50 values 
for both cell types in comparison to 2D cells (0.0783 and 
0.0103 µM PTX for H358 cells, 0.4065 and 0.0878 µM PTX 
for A549 cells for 3D and 2D, respectively). These results 
indicate that spheroids are more resistant to PTX treatment in 
media, likely due to transport limitations into the spheroids 
providing a natural protection to the cells. For AIC condi-
tions, A549 3D spheroids were more resistant to PTX-loaded 
PEGylated phospholipid MPs in comparison to 2D cells 
(991.02 versus 37.78 µg PTX, respectively). Similarly, H358 
3D spheroid were also more resistant to PTX-loaded MPs in 
comparison to 2D where the IC50 values for AIC conditions 
were 5.29 and 20.03 µg for 2D and 3D, respectively. These 
results demonstrate the potential importance of evaluating 
lung anticancer therapeutics in 3D cell culture, as there is a 
significant difference in cellular responses between 2D and 
3D systems. Furthermore, the culturing of lung cancer cells 
in AIC conditions as the resulting cellular responses may 
provide a more physiologically relevant model for anticancer 
therapeutic evaluation when validated against in vivo models 
and/or human clinical trials. In particular, the results reported 
for AIC evaluation were in µg/dose, thereby allowing for a 
simple determination of the dose that should be given to a 
patient in terms of mg/kg via direct inhalation to the lung.
The size of the spheroids was evaluated over time both 
before and after treatment in LCC conditions to determine 
the effect of PTX exposure on the spheroid morphology as 
seen in Fig. 6. For H358 cells, the spheroid sizes increased 
with time and were approximately 150 µm in size after 4 days, 
which is when they were treated with PTX. At 72 h after PTX 
exposure, the spheroid size decreased significantly for cells 
exposed to 0.01, 0.1 and 1 µM of PTX whereas those exposed 
to 0.0001 and 0.001 µM PTX did not differ significantly from 
the control (p<0.05). Thus, there is a threshold value at which 
spheroid dissociation may occur when treating with PTX. 
A549 spheroids increased in size with time, reaching approxi-
mately 60 µm in diameter after 9 days, which is when they 
were treated with PTX. At 72 h after treatment, the spheroid 
sizes decreased for cells exposed to 0.01, 0.1 and 1 µM as with 
Figure 6. Fluorescent micrographs of spheroids grown in LCC conditions on the final day of raw PTX treatment. (A-F) are H358 cells exposed to 0, 0.0001, 
0.001, 0.01, 0.1 and 1 µM in corresponding order. (G-L) are A549 cells exposed to 0, 0.0001, 0.001, 0.01, 0.1 and 1 µM in corresponding order. Scale bar, 200 µm.
Figure 7. Transepithelial electric resistance (TEER) evaluation of Calu-3 monolayers grown in LCC (A) and AIC (b) conditions after exposure to paclitaxel 
and paclitaxel-loaded microparticles, respectively. Approximately 1 mg/well of liposphere particles were applied to each AIC sample.
Table II. IC50 values for A549 and H358 2D cells and 3D 
spheroids in both LCC and AIC conditions.
  LCC AIC
 Culture PTX IC50 PTX IC50
Cells condition (µM) (µg/dose)
H358 2D 0.013 20.0
 3D 0.084 39.2
A549 2D 0.084 5.3
 3D 0.334 991.0
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the H358 cells and remained the same size when exposed to 
0.0001 and 0.001 µM of PTX.
Transepithelial resistance (TEER) was evaluated by 
exposing 2D Calu-3 cells in AIC conditions to PEGylated 
phospholipid MPs containing PTX and LCC conditions to 
PTX in media. Fig. 7 shows the measured resistance of the 
Calu-3 cells after the described treatments up to five days 
where the initial treatment was done after the cells reached 
resistance equilibrium, which are similar to those previously 
reported in literature (31). For LCC cells, the resistance 
continued to increase for all systems up to five days, however, 
for cells exposed to 0.01 and 1 µM PTX the resistance was 
initially stagnant before recovering and increasing with 
time. For AIC cells exposed to MPs, the resistance initially 
decreased for all cells (including the control) which is likely 
due to the addition of media, which could dilute any mucin 
present on the cell layers, thereby decreasing the resistance. 
Cells exposed to 25% PTX exhibited the most significant 
decrease in resistance along with those exposed to 5% PTX, 
however, all samples recovered to the control resistance 
after 5 days (no significant difference, p<0.05). These results 
demonstrate that while dry powder PEGylated phospholipid 
MPs used for aerosol delivery may initially have a detri-
mental effect on lung tissue, that it will subsequently recover 
and likely only result in temporary morbidity.
Overall, the given results demonstrate the validity of using 
an AIC 3D spheroid model in the evaluation of lung anti-
cancer therapeutics, which is the first time this has been done. 
PEGylated phospholipid microparticles loaded with paclitaxel 
were evaluated by cells grown in AIC conditions, whereas 
PTX in media was evaluated by cells in 3D conditions. The 
actual PTX loading and resulting activity of the PTX in the 
particles was favorable (high loading and increased efficacy 
with particle delivery). Furthermore, the difference in cellular 
response in terms of 2D versus 3D and AIC versus LCC 
culturing conditions was demonstrated. Finally, the safety 
of the MPs was demonstrated by TEER evaluation. These 
methods provide the means to more thoroughly characterize 
dry powder aerosol particles (AIC conditions) and solution-
based aerosol particles (LCC conditions) for lung cancer 
aerosol therapeutics.
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